Product Description: GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC50 range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration Cmax of 549 ng/mL, a half-life T1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse[1].
Formula: C29H30N4O2
References: [1]Lu Y, et al., Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19[J]. bioRxiv, 2024: 2024.04. 03.587743.
Molecular Weight: 466.57
Research Area: Infection
Solubility: 10 mM in DMSO
Target: SARS-CoV;Virus Protease